BR0213554A - Timosina para aumento da imunização genética - Google Patents

Timosina para aumento da imunização genética

Info

Publication number
BR0213554A
BR0213554A BR0213554-0A BR0213554A BR0213554A BR 0213554 A BR0213554 A BR 0213554A BR 0213554 A BR0213554 A BR 0213554A BR 0213554 A BR0213554 A BR 0213554A
Authority
BR
Brazil
Prior art keywords
hepatitis
virus
thymosin
genetic immunization
increased genetic
Prior art date
Application number
BR0213554-0A
Other languages
English (en)
Inventor
Jack R Wands
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Publication of BR0213554A publication Critical patent/BR0213554A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"TIMOSINA PARA AUMENTO DA IMUNIZAçãO GENéTICA". A presente invenção descreve o uso de timosina para aumento das respostas imunes celulares ao vírus da hepatite C. Métodos para imunização de um indivíduo suscetível à infecção pelo vírus da hepatite C contra tal infecção compreendendo administração ao indivíduo de um ou mais polinucleotídeos que codificam um ou mais peptídeos do vírus da hepatite C, em combinação com uma ou mais timosinas, são descritos. Composições adequadas para imunização contra o vírus da hepatite C, compreendendo um ou mais polinucleotídeos que codificam um ou mais peptídeos do vírus da hepatite C e uma ou mais timosinas, são também descritas.
BR0213554-0A 2001-10-26 2002-10-28 Timosina para aumento da imunização genética BR0213554A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33063801P 2001-10-26 2001-10-26
PCT/US2002/034535 WO2003035010A2 (en) 2001-10-26 2002-10-28 Thymosin augmentation of genetic immunization

Publications (1)

Publication Number Publication Date
BR0213554A true BR0213554A (pt) 2004-10-26

Family

ID=23290629

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213554-0A BR0213554A (pt) 2001-10-26 2002-10-28 Timosina para aumento da imunização genética

Country Status (21)

Country Link
US (1) US20050054845A1 (pt)
EP (1) EP1448223B1 (pt)
JP (1) JP2005506997A (pt)
KR (1) KR100902197B1 (pt)
CN (1) CN1269524C (pt)
AT (1) ATE382365T1 (pt)
BR (1) BR0213554A (pt)
CA (1) CA2464795A1 (pt)
CY (1) CY1107371T1 (pt)
DE (1) DE60224435T2 (pt)
DK (1) DK1448223T3 (pt)
EA (1) EA006743B1 (pt)
ES (1) ES2299626T3 (pt)
IL (1) IL161603A0 (pt)
MX (1) MXPA04003867A (pt)
NO (1) NO20042124L (pt)
NZ (1) NZ532863A (pt)
PL (1) PL370453A1 (pt)
PT (1) PT1448223E (pt)
UA (1) UA81613C2 (pt)
WO (1) WO2003035010A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1835931A4 (en) * 2004-12-06 2008-12-17 Sciclone Pharmaceuticals Inc ALPHA THYMOSINE PEPTIDES AS CANCER VACCINE ADJUVANTIES
US8716012B2 (en) 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
TW224053B (pt) * 1991-09-13 1994-05-21 Paul B Chretien
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6288033B1 (en) * 1998-09-25 2001-09-11 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir

Also Published As

Publication number Publication date
US20050054845A1 (en) 2005-03-10
JP2005506997A (ja) 2005-03-10
CY1107371T1 (el) 2012-12-19
DK1448223T3 (da) 2008-02-18
CN1269524C (zh) 2006-08-16
WO2003035010A3 (en) 2003-12-04
PT1448223E (pt) 2008-01-23
EA006743B1 (ru) 2006-04-28
IL161603A0 (en) 2004-09-27
CA2464795A1 (en) 2003-05-01
EP1448223A2 (en) 2004-08-25
NO20042124L (no) 2004-05-24
EA200400534A1 (ru) 2004-12-30
ES2299626T3 (es) 2008-06-01
PL370453A1 (en) 2005-05-30
KR20040089075A (ko) 2004-10-20
KR100902197B1 (ko) 2009-06-11
MXPA04003867A (es) 2005-06-17
EP1448223A4 (en) 2005-11-16
WO2003035010A2 (en) 2003-05-01
ATE382365T1 (de) 2008-01-15
DE60224435T2 (de) 2009-01-02
NZ532863A (en) 2006-07-28
DE60224435D1 (de) 2008-02-14
CN1604789A (zh) 2005-04-06
EP1448223B1 (en) 2008-01-02
UA81613C2 (ru) 2008-01-25

Similar Documents

Publication Publication Date Title
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
DK0587780T3 (da) Smitstof, som forårsager Mystery Swine Disease, vaccinepræparater og diagnostiske sæt
BR9913446A (pt) Produtos de aglicona e métodos de uso
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
ATE103297T1 (de) Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea.
MXPA05005203A (es) Vacuna contra vhc.
DE69432137D1 (de) Impfstoff gegen Geflügelkokzidose
BR0207018A (pt) Leptina modificada com imunogenicidade reduzida
BR0016129A (pt) Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto
DE69635472D1 (de) Impfstoff gegen Geflügelkokzidose
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
BR0207704A (pt) Alfa interferon modificado com imunogenicidade reduzida
SE9604581D0 (sv) An agent against cancer and virus infections
BR0213554A (pt) Timosina para aumento da imunização genética
DE69521007D1 (de) Impfstoff gegen Geflügelkokzidose
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
KR960700741A (ko) 인터페론치료에 대한 무응답자의 c형 간염 치료방법(method of treating hepatitis c in non-pesponders to interferon treatment)
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
BRPI0514274A (pt) vìrus de varìola aviária recombinante e composição farmacêutica para induzir uma resposta imune celular especìfica contra o vhc

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.